The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study.
D. A. Pollyea
Research Funding - Celgene
H. E. Kohrt
No relevant relationships to disclose
L. Gallegos
No relevant relationships to disclose
B. Zhang
No relevant relationships to disclose
M. Figueroa
No relevant relationships to disclose
A. Melnick
No relevant relationships to disclose
C. Berube
No relevant relationships to disclose
S. E. Coutre
No relevant relationships to disclose
J. R. Gotlib
No relevant relationships to disclose
J. L. Zehnder
No relevant relationships to disclose
M. Liedtke
Research Funding - Celgene
B. S. Mitchell
No relevant relationships to disclose
B. C. Medeiros
Research Funding - Cylene